278 related articles for article (PubMed ID: 17020440)
1. Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?
Doggrell SA
Expert Opin Pharmacother; 2006 Oct; 7(15):2169-73. PubMed ID: 17020440
[TBL] [Abstract][Full Text] [Related]
2. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A;
JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409
[TBL] [Abstract][Full Text] [Related]
3. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes.
Donovan DM; Anton RF; Miller WR; Longabaugh R; Hosking JD; Youngblood M;
J Stud Alcohol Drugs; 2008 Jan; 69(1):5-13. PubMed ID: 18080059
[TBL] [Abstract][Full Text] [Related]
4. Relationship between medication adherence and treatment outcomes: the COMBINE study.
Zweben A; Pettinati HM; Weiss RD; Youngblood M; Cox CE; Mattson ME; Gorroochurn P; Ciraulo D
Alcohol Clin Exp Res; 2008 Sep; 32(9):1661-9. PubMed ID: 18616687
[TBL] [Abstract][Full Text] [Related]
5. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
Greenfield SF; Pettinati HM; O'Malley S; Randall PK; Randall CL
Alcohol Clin Exp Res; 2010 Oct; 34(10):1803-12. PubMed ID: 20645934
[TBL] [Abstract][Full Text] [Related]
6. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
Feeney GF; Connor JP; Young RM; Tucker J; McPherson A
Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406
[TBL] [Abstract][Full Text] [Related]
7. Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Capone C; Kahler CW; Swift RM; O'Malley SS
J Stud Alcohol Drugs; 2011 Jan; 72(1):135-40. PubMed ID: 21138720
[TBL] [Abstract][Full Text] [Related]
8. Cannabis use during treatment for alcohol use disorders predicts alcohol treatment outcomes.
Subbaraman MS; Metrik J; Patterson D; Swift R
Addiction; 2017 Apr; 112(4):685-694. PubMed ID: 27865015
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
10. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
Mann K; Lemenager T; Hoffmann S; Reinhard I; Hermann D; Batra A; Berner M; Wodarz N; Heinz A; Smolka MN; Zimmermann US; Wellek S; Kiefer F; Anton RF;
Addict Biol; 2013 Nov; 18(6):937-46. PubMed ID: 23231446
[TBL] [Abstract][Full Text] [Related]
11. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
Zarkin GA; Bray JW; Aldridge A; Mitra D; Mills MJ; Couper DJ; Cisler RA;
Arch Gen Psychiatry; 2008 Oct; 65(10):1214-21. PubMed ID: 18838638
[TBL] [Abstract][Full Text] [Related]
12. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
[TBL] [Abstract][Full Text] [Related]
13. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
Soyka M; Chick J
Am J Addict; 2003; 12(s1):s69-s80. PubMed ID: 14972781
[TBL] [Abstract][Full Text] [Related]
14. New pharmacotherapies for alcohol dependence.
Graham R; Wodak AD; Whelan G
Med J Aust; 2002 Jul; 177(2):103-7. PubMed ID: 12098353
[TBL] [Abstract][Full Text] [Related]
15. Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.
Gueorguieva R; Wu R; Krystal JH; Donovan D; O'Malley SS
Addict Behav; 2013 May; 38(5):2119-27. PubMed ID: 23435273
[TBL] [Abstract][Full Text] [Related]
16. Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study.
Weiss RD; O'malley SS; Hosking JD; Locastro JS; Swift R;
J Stud Alcohol Drugs; 2008 Nov; 69(6):878-84. PubMed ID: 18925346
[TBL] [Abstract][Full Text] [Related]
17. Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study.
Ray LA; Oslin DW
Drug Alcohol Depend; 2009 Dec; 105(3):256-8. PubMed ID: 19717248
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
Snyder JL; Bowers TG
Am J Drug Alcohol Abuse; 2008; 34(4):449-61. PubMed ID: 18584575
[TBL] [Abstract][Full Text] [Related]
19. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment.
Mason BJ
Eur Neuropsychopharmacol; 2003 Dec; 13(6):469-75. PubMed ID: 14636963
[TBL] [Abstract][Full Text] [Related]
20. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]